18889881171
Kalkine 0
countryflagUS

Avicanna Inc

Healthcare US AVCNF

0.185USD
-0.005(2.63%)

Last update at 2025-07-07T20:00:00Z

Day Range

0.190.19
LowHigh

52 Week Range

0.180.45
LowHigh

Fundamentals

  • Previous Close 0.19
  • Market Cap27.23M
  • Volume10000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.10219M
  • Revenue TTM11.87M
  • Revenue Per Share TTM0.15
  • Gross Profit TTM 1.12M
  • Diluted EPS TTM-0.13

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.73529M -16.76077M -35.04930M -23.24643M -7.28940M
Minority interest - - 7.89M 7.49M 8.07M
Net income -14.73529M -16.77454M -32.86170M -21.07197M -7.09906M
Selling general administrative 9.99M 12.88M 16.24M 21.18M 7.81M
Selling and marketing expenses - - - - -
Gross profit 1.12M 2.83M -0.57012M 0.09M -0.00431M
Reconciled depreciation 0.89M 0.89M 1.09M 0.92M 0.17M
Ebit - -11.41341M -18.98841M -23.22358M -8.44610M
Ebitda -12.17612M -15.12873M -33.69920M -22.26815M -8.15111M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -10.41042M -11.41341M -18.98841M -23.22358M -8.32381M
Other operating expenses - - - - -
Interest expense 1.67M 0.74M 0.26M 0.05M 0.00000M
Tax provision 0.00000M 0.01M -2.18760M -1.03339M -
Interest income - - 0.00000M 0.07M 0.01M
Net interest income -1.67184M -0.73806M -0.26311M 0.01M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.01M -2.18760M -1.03339M -
Total revenue 4.05M 3.27M 1.57M 0.17M 0.12M
Total operating expenses 14.46M 14.68M 20.56M 23.39M 8.44M
Cost of revenue 2.93M 0.44M 2.14M 0.08M 0.12M
Total other income expense net -2.65303M -4.60931M -15.79778M -0.03702M 1.02M
Discontinued operations - - - - -
Net income from continuing ops -14.73529M -16.77454M -32.86170M -22.21304M -7.28940M
Net income applicable to common shares -14.73529M -16.77454M -32.86170M -22.21304M -7.09906M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 17.62M 22.30M 30.16M 45.16M 28.18M
Intangible assets 0.17M 0.30M 0.50M 11.06M 10.73M
Earning assets - - - - -
Other current assets - 1.08M 0.65M 0.12M -
Total liab 14.16M 15.39M 16.25M 15.29M 1.80M
Total stockholder equity -0.38356M 1.15M 6.02M 22.39M 18.31M
Deferred long term liab - - - - -
Other current liab 0.00097M 3.66M 4.49M 3.32M 1.46M
Common stock - 66.24M 57.47M 46.03M 21.49M
Capital stock 74.89M 66.24M 57.47M 46.03M 21.49M
Retained earnings -90.82924M -77.40747M -62.03624M -30.80044M -9.72846M
Other liab 2.35M 2.78M 3.26M 5.52M 3.21M
Good will - - 0.00000M 3.21M -
Other assets - - 0.56M 3.78M -
Cash 1.19M 0.03M 1.27M 0.44M 0.07M
Cash and equivalents - - - - -
Total current liabilities 11.41M 12.20M 12.82M 8.72M 1.79M
Current deferred revenue - - - - -
Net debt 1.64M 1.47M 0.31M 0.27M -
Short term debt - - - 3.32M -
Short long term debt 2.66M 1.09M 1.57M 3.32M -
Short long term debt total - - - - -
Other stockholder equity - 12.31M 10.58M 7.15M 6.55M
Property plant equipment - 14.47M 21.81M 23.16M 16.26M
Total current assets 7.06M 7.35M 6.77M 3.95M 1.19M
Long term investments 0.00000M 0.18M 0.52M 0.00007M 0.00007M
Net tangible assets - 0.85M 5.52M 8.12M 4.37M
Short term investments - 0.00000M 1.25M - 0.00000M
Net receivables 2.12M 2.34M 1.01M 1.20M 0.26M
Long term debt 0.18M 0.42M - 0.72M 0.01M
Inventory 3.24M 3.00M 1.28M 1.48M -
Accounts payable 4.75M 7.29M 6.56M 5.18M 1.46M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 41.21M 26.99M
Deferred long term asset charges - - - - -
Non current assets total 10.55M 14.95M 23.39M 41.21M 26.99M
Capital lease obligations 0.37M 0.16M 0.36M 0.56M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.81M 1.25M -1.25000M -1.25000M 0.00993M
Change to liabilities 0.00000M 0.81M 1.38M 4.16M 0.82M
Total cashflows from investing activities 0.81M 0.76M -2.70711M -8.75726M -7.04042M
Net borrowings - 0.88M 4.53M 3.20M 0.42M
Total cash from financing activities 9.90M 10.06M 17.39M 26.91M 10.92M
Change to operating activities - -0.01237M -1.16698M 0.07M 0.34M
Net income -14.73529M -16.77454M -32.86170M -22.21304M -7.09906M
Change in cash 3.28M -1.23573M 0.82M 0.37M -1.10725M
Begin period cash flow 0.03M 1.27M 0.44M 0.07M 1.18M
End period cash flow 1.19M 0.03M 1.27M 0.44M 0.07M
Total cash from operating activities -7.43537M -11.66302M -13.97045M -17.77103M -4.99079M
Issuance of capital stock 9.08M 9.09M 12.86M 0.00000M 5.66M
Depreciation 0.89M 0.76M 0.98M 0.90M 0.17M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.87M -1.72598M 0.21M -1.50710M -1.50710M
Change to account receivables 0.37M -1.49918M -0.51595M -1.13624M -0.18327M
Sale purchase of stock - - - - -
Other cashflows from financing activities 1.89M 2.31M 2.52M 1.57M 4.18M
Change to netincome - 6.67M 17.87M 1.93M 0.96M
Capital expenditures 0.07M 0.77M 1.62M 7.92M 3.87M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.43M -2.44901M 0.46M 1.34M 0.98M
Stock based compensation 1.04M 1.31M 3.12M 2.69M -
Other non cash items 2.52M -0.01348M 0.26M 4.14M 0.84M
Free cash flow -7.50215M -12.45226M -15.42757M -26.93911M -8.90916M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVCNF
Avicanna Inc		 -0.005 2.63% 0.18 - - 2.25 33.39 2.34 -2.5937
ZTS
Zoetis Inc		 1.31 0.83% 158.36 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.61 2.38% 26.22 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 129.30 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.025 0.17% 15.04 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Avicanna Inc

480 University Avenue, Toronto, ON, Canada, M5G 1V2

Key Executives

Name Title Year Born
Mr. Aras Azadian B.Econ, Mba Co-Founder, CEO & Director NA
Dr. Frantz Le Devedec Exec. VP of R&D NA
Mr. Roland Alvarez SVP of Technical Operations NA
Ms. Ivana Maric Exec. VP of Marketing NA
Dr. Carlos Enrique Maldonado Muete SVP of Clinical Devel. NA
Ms. Caitlin Johnston Sr. VP of Strategic Partnerships & Patient Access NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.